Europe’s Pharmaceutical Framework has Been Reopened
Two decades after the first Medicinal Products Regulation and Directive was adopted, the EU is re-opening a pandora’s box of legislation in response to long-standing concerns that the current European pharmaceutical framework does not go far enough to address unmet medical needs, inequities in access to approved therapies and the burden of rising costs on national health care budgets...Read More
Which direction for EU health policy after the pandemic?
The institutional questions the pandemic has raised about the EU’s role in health will not disappear. With the forthcoming revision of the EU pharmaceutical legislation, larger EU countries set the direction of the European pharmaceutical market for decades to come. ..Read More